Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement
- PMID: 31774251
- PMCID: PMC6928032
- DOI: 10.1111/irv.12697
Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement
Abstract
The threat of novel influenza infections has sparked research efforts to develop subunit vaccines that can induce a more broadly protective immunity by targeting selected regions of the virus. In general, subunit vaccines are safer but may be less immunogenic than whole cell inactivated or live attenuated vaccines. Hence, novel adjuvants that boost immunogenicity are increasingly needed as we move toward the era of modern vaccines. In addition, targeting, delivery, and display of the selected antigens on the surface of professional antigen-presenting cells are also important in vaccine design and development. The use of nanosized particles can be one of the strategies to enhance immunogenicity as they can be efficiently recognized by antigen-presenting cells. They can act as both immunopotentiators and delivery system for the selected antigens. This review will discuss on the applications, advantages, limitations, and types of nanoparticles (NPs) used in the preparation of influenza subunit vaccine candidates to enhance humoral and cellular immune responses.
Keywords: immunogenicity; influenza vaccine; nanoparticles; subunit vaccine; vaccine delivery.
© 2019 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
Similar articles
-
Preparation, characterization and immunological evaluation of alginate nanoparticles loaded with whole inactivated influenza virus: Dry powder formulation for nasal immunization in rabbits.Microb Pathog. 2018 Feb;115:74-85. doi: 10.1016/j.micpath.2017.12.011. Epub 2017 Dec 6. Microb Pathog. 2018. PMID: 29223454
-
Combined Intranasal Nanoemulsion and RIG-I Activating RNA Adjuvants Enhance Mucosal, Humoral, and Cellular Immunity to Influenza Virus.Mol Pharm. 2021 Feb 1;18(2):679-698. doi: 10.1021/acs.molpharmaceut.0c00315. Epub 2020 Jun 15. Mol Pharm. 2021. PMID: 32491861
-
Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.J Prev Med Hyg. 2009 Jun;50(2):121-6. J Prev Med Hyg. 2009. PMID: 20099444
-
Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines.Hum Vaccin Immunother. 2013 Mar;9(3):582-90. doi: 10.4161/hv.23239. Epub 2013 Jan 7. Hum Vaccin Immunother. 2013. PMID: 23295230 Free PMC article. Review.
-
MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.Expert Rev Vaccines. 2007 Oct;6(5):659-65. doi: 10.1586/14760584.6.5.659. Expert Rev Vaccines. 2007. PMID: 17931147 Review.
Cited by
-
Encapsulation of the lipidated TLR7/8 agonist INI-4001 into ionic liposomes impacts H7 influenza antigen-specific immune responses.Drug Deliv Transl Res. 2025 Jul 14. doi: 10.1007/s13346-025-01917-6. Online ahead of print. Drug Deliv Transl Res. 2025. PMID: 40660065 No abstract available.
-
Influenza Virus-Derived CD8 T Cell Epitopes: Implications for the Development of Universal Influenza Vaccines.Immune Netw. 2024 May 7;24(3):e19. doi: 10.4110/in.2024.24.e19. eCollection 2024 Jun. Immune Netw. 2024. PMID: 38974213 Free PMC article. Review.
-
Layered Double Hydroxides: Recent Progress and Promising Perspectives Toward Biomedical Applications.Adv Sci (Weinh). 2024 May;11(20):e2306035. doi: 10.1002/advs.202306035. Epub 2024 Mar 19. Adv Sci (Weinh). 2024. PMID: 38501901 Free PMC article. Review.
-
SARS-CoV-2: vaccinology and emerging therapeutics; challenges and future developments.Ther Deliv. 2022 Mar;13(3):187-203. doi: 10.4155/tde-2021-0075. Epub 2022 Feb 23. Ther Deliv. 2022. PMID: 35195017 Free PMC article. Review.
-
Zinc Carnosine Metal-Organic Coordination Polymer as a Potent Broadly Active Influenza Vaccine Platform with In Vitro Shelf-Stability.Mol Pharm. 2023 Sep 4;20(9):4687-4697. doi: 10.1021/acs.molpharmaceut.3c00424. Epub 2023 Aug 21. Mol Pharm. 2023. PMID: 37603310 Free PMC article.
References
-
- WHO . Influenza fact sheet. 2018. http://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal). Accessed November 6, 2018.
-
- Subbarao K, Murphy BR, Fauci AS. Development of effective vaccines against pandemic influenza. Immunity. 2006;24(1):5‐9. - PubMed
-
- Khurana S, Loving CL, Manischewitz J, et al. Vaccine‐induced anti‐HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med. 2013;5(200):200ra114. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical